By 2023, approximately 1 in 5 patients with non-small cell lung cancer or metastatic colorectal cancer were treated with a bevacizumab biosimilar.
Use of biosimilars to Avastin (bevacizumab) increased to about one-fifth of patients with non-small cell lung cancer and metastatic colorectal cancer by March 2024, according to results of a real-world evidence study presented at the 2025 annual meeting of the Academy of Managed Care Pharmacy (AMCP) this week in Houston.
The research also showed that hemorrhage was more common among patients with non-small cell lung cancer treated with the Avastin biosimilars than those treated with “originator” Avastin (6.4% vs. 4.7%) but less common in patients with metastatic colorectal cancer treated with Avastin biosimilars (9.1% vs. 9.9%).
Four Avastin biosimilars have launched, starting with Mvasi (bevacizumab-awwb) in July 2019, followed by Zirabev (bevacizumab-bvzr), Vegzelma (bevacizumab-adcd) and Alymys (bevacizumab-maly). Bevacizumab inhibits vascular endothelial growth factor (VEGF), a protein that helps spur the growth of blood vessels that supply tumors with oxygen and nutrients.
Cate Lockhart, Pharm.D., Ph.D.
Cate Lockhart, Pharm.D., Ph.D., chief science officer of AMCP and executive director at Biologics and Biosimilars Collective Intelligence Consortium, and her co-researchers used deidentified data from Carelon Research’s Healthcare Integrated Research Data from July 1, 2017, through March 31, 2024. Carelon is a research arm of Elevance Health, formerly known as Anthem, one of the largest health insurance companies in the U.S. They identified 1,307 patients with non-small cell lung cancer and metastatic colorectal cancer and 4,688 patients with metastatic colorectal cancer. Among the patients with non-small cell lung cancers, the proportion treated with Avastin biosimilars increased from 0% in 2018 to 23.9% in 2023. The pattern was similar among those with metastatic colorectal cancer, with the proportion increasing from 0% in 2018 to 21.8% in 2023. Over the same time period, the use of Avastin fell from 14.9% to 11.9% among the patients with non-small cell lung cancer, which accounts for approximately 80% of lung cancers, and from 22.9% to 7.4%.
Although adverse outcomes varied between cohorts, Lockhart and her colleagues concluded that the efficacy and safety of Avastin biosimilars were comparable to the originator and that the originator and biosimilar were used by similar patients.
AMCP Keynote Speaker Vin Gupta Says Future of Healthcare is Digital | AMCP Annual 2025
April 1st 2025Digital solutions are needed in healthcare now so that more patients can get the access that they need, according to Vin Gupta, M.D., MPA, former chief medical officer of Amazon Pharmacy and a leading health policy expert.
Read More
Prime Therapeutics Finds No Medical Cost Offsets for GLP-1 Obesity Drugs | AMCP Annual 2025
April 1st 2025A Prime Therapeutics analysis of real-world data has found that medical costs for patients taking GLP-1 drugs for obesity had increased by about $1,338 per member, compared with a matched control group.
Read More
Emerging Therapies Committee at UC Davis Hits the Accelerator Not the Brake | AMCP 2024
April 18th 2024After the onboarding of cell and gene therapy bogged using normal pharmacy and therapeutics (P&T) committee procedures, UC Davis Health set up an emerging therapeutics committee to streamline and speed up the process of delivery expensive cell and gene therapies.
Read More
Potential Generics Could Lower Prices for Oncology, Cardiovascular Drugs | AMCP 2024
April 18th 2024Up to 50 generics could be approved this year, including Victoza to treat patients with diabetes. If generics of Victoza become available, this would the first GLP-1 to face generic competition.
Read More